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Abstract Chronic obstructive pulmonary disease, COPD,
affects the condition of the entire human organism and
causes multiple comorbidities. Pathological lung changes
lead to quantitative changes in the composition of the
metabolites in different body fluids. The obstructive sleep
apnea syndrome, OSAS, occurs in conjunction with
chronic obstructive pulmonary disease in about 10–20 % of
individuals who have COPD. Both conditions share the
same comorbidities and this makes differentiating them
difficult. The aim of this study was to investigate whether it
is possible to diagnose a patient with either COPD or the
OSA syndrome using a set of selected metabolites and to
determine whether the metabolites that are present in one
type of biofluid (serum, exhaled breath condensate or
urine) or whether a combination of metabolites that are
present in two biofluids or whether a set of metabolites that
are present in all three biofluids are necessary to correctly
diagnose a patient. A quantitative analysis of the metabo-
lites in all three biofluid samples was performed using 1H
NMR spectroscopy. A multivariate bootstrap approach that
combines partial least squares regression with the variable
importance in projection score (VIP-score) and selectivity
ratio (SR) was adopted in order to construct discriminant
diagnostic models for the groups of individuals with COPD
and OSAS. A comparison study of all of the discriminant
models that were constructed and validated showed that the
discriminant partial least squares model using only ten
urine metabolites (selected with the SR approach) has a
specificity of 100 % and a sensitivity of 86.67 %. This
model (AUCtest = 0.95) presented the best prediction
performance. The main conclusion of this study is that
urine metabolites, among the others, present the highest
probability for correctly identifying patents with COPD
and the lowest probability for an incorrect identification of
the OSA syndrome as developed COPD. Another important
conclusion is that the changes in the metabolite levels of
exhaled breath condensates do not appear to be specific
enough to differentiate between patients with COPD and
OSAS.
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Abbreviations
COPD Chronic obstructive pulmonary disease
HCA Hierarchical clustering analysis
OSAS Obstructive sleep apnea syndrome
NMR Nuclear magnetic resonance
EBC Exhaled breath condensate
GC/LC–MS Gas/liquid chromatography–mass
spectrometry
PCA Principal component analysis
PLS-DA Partial least squares-discriminant analysis
LDA Linear discriminant analysis
OPLS Orthogonal partial least squares
OPLS-DA Orthogonal partial least squares-
discriminant analysis
ANOVA-PCA Analysis of variance-principal component
analysis
ANOVA-SCA Analysis of variance-simultaneous
component analysis
VIP-score Variable importance in projection-score
SR Selectivity ratio
TSP 3-(Trimethylsilyl)-2,20,3,30-
tetradeuteropropionate sodium salt TSP-
d4
AUC Area under the curve
DIVA test Discriminating variable test
L1 LDL CH3–(CH2)n–
L2 VLDL CH3–(CH2)n–
L3 LDL CH3–(CH2)n–/VLDL CH3–(CH2)n–
L4 VLDL –CH2–CH2–C=O–
L5 CH2–CH=CH–
L6 Unsaturated lipids –CH=CH–
NAC1 N-Acetylated glycoprotein 1
NAC2 N-Acetylated glycoprotein 2
1 Introduction
Chronic obstructive pulmonary disease, COPD, is a pre-
ventable and treatable disease that is characterized by a
progressive and persistent airflow limitation which is the
result of chronic inflammation (Global Strategy for Diag-
nosis, Management, and Prevention of COPD 2014).
Pathological changes in COPD occur in small airways,
lung parenchyma and small pulmonary vessels. Morpho-
logical changes in COPD include fibrosis and narrowing of
small airways, together with parenchymal and alveolar
destruction. This results in air trapping, emphysema, per-
sistent lung hyperinflation and impaired exchange of gases
(Hogg 2004; Baraldo et al. 2012). Consequently, patients
with severe COPD suffer from respiratory insufficiency,
pulmonary hypertension and right ventricular failure. A
cornerstone of those morphological changes is an abnormal
inflammatory response to noxious particles or gases with
repeated tissue injury and repair (Go´rska et al. 2010;
Barnes 2014). Inflammatory infiltrations are characterized
by a cell pattern that has an increased number of alveolar
macrophages, neutrophils and cytotoxic T-lymphocytes,
which release various inflammatory mediators (Pappas
et al. 2013; Barnes et al. 2003). The mechanism of am-
plifications and alterations in the inflammatory response in
COPD patients probably depend on genetic and environ-
mental factors that are not yet fully understood. An im-
balance in proteases–antiproteases and repeated oxidative
stress are involved in the process and biomarkers of ox-
idative stress are usually present in the biofluids (serum,
exhaled breath condensate, sputum and urine) that are
collected from COPD patients (Pillai et al. 2009; Castaldi
et al. 2010; Kohansal et al. 2009; Stockley 2013; Vestbo
and Rennard 2010).
Obstructive sleep apnea syndrome, OSAS, is defined as
a sleep disorder in which an individual has 15 or more
episodes of apnea or hypopnea per hour (apnea/hypopnea
index, AHI C 15) or AHI C 5 with associated symptoms
like fatigue, impaired cognition and/or increased daytime
sleepiness (Park et al. 2011). The episodes of apnea
typically last 20–40 s and result from an obstruction of the
upper airways in adults, which is usually due to a pha-
ryngeal collapse. Obesity is considered to be the most
important predisposing factor as it causes an accumulation
of fat in the peripharyngeal tissues (Romero-Corral et al.
2010; Tuomilehto et al. 2013). The OSA syndrome is often
associated with other anatomical alterations that reduce the
lumen of the pharynx, e.g. a thickening of the lateral
parapharyngeal muscular walls or an increase in the length
of the pharynx. The narrow airways are generally more
prone to collapse than the larger ones (the Venturi effect)
and this causes a further reduction of their lumen. The
pharynx is kept patent mainly by the proper activity of
dilator pharyngeal muscles. It was demonstrated that dur-
ing sleep, this activity declines physiologically due to a
decrease in the reflex mechanisms from chemoreceptors
and mechanoreceptors. Consequently, while sleeping, the
under stimulated muscles cannot always allow airflow in
individuals with narrow upper airways, and the OSA syn-
drome occurs (Jordan and White 2008).
The pathogenic factors in both conditions are different
and do not increase the risk of their incidence. The
prevalence of COPD in the patients with the OSA syn-
drome is in the range of 10–20 %. However, COPD and
OSAS share common comorbidities, especially cardiovas-
cular diseases, which may be linked to the development of
atherosclerosis. For this reason, there has been a growing
interest in finding the chemical compounds (biomarkers)
that reliably and unambiguously indicate COPD or OSAS
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in the recent years. A large number of the research works
that are devoted to the high-throughput analysis of COPD
have mainly been focused on a comparison of the
metabolites in the exhaled breath condensate (EBC) of
individuals with COPD and healthy controls (Bertini et al.
2014; Basanta et al. 2012; Fens et al. 2011; de Laurentiis
et al. 2008). Only a few studies have described the results
of such a comparison using plasma, serum and urine
samples (Wang et al. 2013; McClay et al. 2010; Ubhi et al.
2012). Usually, special attention is paid to the smoking
habits (smokers with or without emphysema) of the sub-
jects who are being investigated (Paige et al. 2011; de
Laurentiis et al. 2013; Ubhi et al. 2012). The collection of
samples is often analyzed using 1H NMR, GC– and/or LC–
MS. A metabolomic approach to the OSA syndrome in-
volves a comparison of the LC–MS fingerprints that are
obtained from plasma samples of patients who have been
diagnosed with the sleep apnea or hypopnea syndrome, and
healthy individuals (Ferrarini et al. 2013). Unsupervised
methods like hierarchical clustering analysis, HCA, and
principal component analysis, PCA, as well as supervised
methods like discriminant partial least squares regression,
PLS-DA, linear discriminant analysis, LDA, orthogonal
partial least squares regression, OPLS-DA, and some re-
cently proposed approaches such as the analysis of vari-
ance-principal component analysis, ANOVA-PCA and the
analysis of variance-simultaneous component analysis have
usually been adopted to describe the data structure or the
discrimination of two or more groups of individuals.
However, the selection of important biomarkers or the
signal intervals that are important for the distinction be-
tween disease entities is often done using a univariate ap-
proach like the t test, the Fisher test or ANOVA.
Subsequently, the set of important variables that has been
selected is used to build a multivariate discriminant/clas-
sification model. Such a univariate approach does not allow
for the selection of a set of potential biomarkers that are
characteristic for the discrimination, because the variable
selection is not performed during the construction of the
discriminant or classification model. In our work, we offer
a more comprehensive approach that uses the principles of
metabolomic data fusion (Bro et al. 2013) and multivariate
variable selection in order to build diagnostic models for
patients with the OSA syndrome and/or COPD. The vari-
ables (metabolites that are analyzed in serum, exhaled
breath condensate and urine) that are relevant to the two-
group discrimination were identified using the bootstrap
PLS-DA procedure combined with the variable importance
in projection score, VIP-score, (Andersen and Bro 2010;
Gosselin et al. 2010) or the selectivity ratio (SR) (Kval-
heim and Karstang 1989; Rajalahti et al. 2009). The SR
approach in PLS-DA has gained much popularity in recent
years (Kvalheim et al. 2014; Kvalheim 2010), because the
possibility of selecting variables that are large in absolute
size, but that are not related to the discrimination of the
model groups, is eliminated throughout the so-called target
projection or target rotation transformation. With the target
projection transformation, several PLS-DA components
(the model’s complexity) are represented by a single pre-
dictive component that is unrelated to the orthogonal var-
iation with the response variable. The same objective is
met by the OPLS method, even though it uses a different
algorithmic procedure. The interest in the SR method can
also be explained by the fact that the predictive component
for OPLS and PLS post-processing by similarity transfor-
mation (Ergon 2005) is identical to the predictive compo-
nent that is obtained from the target projection
transformation except for the scaling factor (Kvalheim
et al. 2009). On the other hand, the variables that are se-
lected using the VIP-score are related to both the response
variable and to the variance of independent variables.
The bootstrap PLS-DA methodology combined with an
estimation of VIP-scores and SRs for different sets of
metabolites was proposed here to investigate: (i) whether it
is possible to diagnose a patient with either the COPD
disease or the OSA syndrome using a set of selected
metabolites and to determine what a probability of false
diagnostic decision is; (ii) whether the metabolites that are
present in one type of biofluid (serum, exhaled breath
condensate or urine) are sufficient enough for this diag-
nosis; (iii) whether a combination of metabolites that are
present in two biofluids or a set of metabolites that is
present in all three biofluids are necessary to correctly di-
agnose a patient (at a certain level of significance).
2 Materials and methods
2.1 Ethics statement
The study was conducted in agreement with the Declara-
tion of Helsinki and was approved by the Ethics Committee
of the Medical University in Wroclaw, Poland. All of the
participants signed an informed consent form (KB-12/
2010).
2.2 Study population comprises
A total of 85 serum, 91 urine and 82 exhaled breath con-
densate samples were collected from adult individuals who
had been diagnosed according to the generally accepted
criteria. Over half of the individuals who were studied have
concomitant cardiovascular disease (CVD) including is-
chemic heart disease and/or arterial hypertension and/or
have suffered a brain stroke. All of these comorbidities
were controlled during the study. Patients with any other
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unstable or acute diseases were excluded from the study.
Finally, 46 individuals (18 patients with COPD and 28
patients with the OSA syndrome) who had had all three
biofluids collected were included in the following targeted
metabolomic data fusion analysis. The demographic data of
those patients are presented in Table 1.
2.3 Preparation of the samples for proton NMR
spectroscopy
Samples of serum, urine and EBC were collected from the
subjects participating in the study in the morning after they
had fasted for at least eight hours. Serum was sampled from
the peripheral vein and centrifuged for 10 min at
40009g. EBC was collected using the EcoScreen Turbo
(VIASYS Healthcare GmbH, Hoechberg, Germany) appa-
ratus according to the manufacturer’s instructions. The
subjects were without a previous oral hygiene and breathed
spontaneously through a mouthpiece while sitting upright
and wearing a nose clip. The sampling procedure was
finished when the EBC sample volume was at least 2 mL.
All of the samples were frozen in liquid nitrogen imme-
diately after collection and stored at -80 C until the
analysis.
Prior to the metabolomic experiment, the serum samples
were thawed at room temperature and vortexed. Next,
mixtures of 200 lL of serum and 400 lL of saline solution
(prepared from 0.9 % NaCl, 15 % D2O and 3 mM TSP)
were mixed again. After centrifugation (12,0009g,
10 min), an aliquot of 550 lL of each sample supernatant
was subsequently transferred into a 5 mm NMR tubes.
Samples were kept at 4 C until the measurement.
All urine samples were thawed at room temperature and
mixed using a vortex mixer. The samples were centrifuged
for 10 min at 12,0009g and 400 lL of supernatant was
then transferred into a new Eppendorf tube. Next, the
samples were mixed with 200 lL of PBS (0.5 M, pH 7.00,
33 % D2O, 3 mM NaN3 and 3 mM TSP). The samples
were mixed again and finally, an aliquot of 550 lL was
transferred into a 5 mm NMR tube.
The EBC samples were thawed at room temperature and
mixed using a vortex mixer. Aliquots of 250 lL D2O
(3 mM TSP, 3 mM NaN3) were added to 300 lL EBC.
After centrifugation (10,0009g for 10 min), 500 lL sam-
ples of the clarified solutions were transferred into 5 mm
NMR tubes.
2.4 1H NMR measurements
The NMR spectra of the serum and urine samples were
recorded at 300 K using an Avance II spectrometer
(Bruker, GmBH, Germany) operating at a proton frequency
of 600.58 MHz, while the NMR spectra of the EBC sam-
ples were recorded at 300 K using an Avance III spec-
trometer (Bruker, GmBH, Germany) operating at proton
QCI CryoProbe frequency of 700 MHz.
The NMR spectra of the serums were recorded by using
a CPMG pulse sequence with water presaturation on a
Bruker notation. For each sample, 128 sequential scans
were collected with spin-echo delay of 400 ls; 80 loops; a
relaxation delay of 3.5 s; an acquisition time of 2.73 s; TD
of 64 k; SW of 20.01 ppm.
The NMR spectra of the urine samples were recorded
using nuclear Overhauser effect spectroscopy, NOESY
pulse sequence with water presaturation on a Bruker no-
tation: a relaxation delay of 3.5 s; an acquisition time of
1.36 s; 128 transients; TD of 32 k; SW of 20.01 ppm.
The NMR spectra of the EBC samples were recorded
using the excitation sculpting (ZGESGP) pulse sequence
with water presaturation on a Bruker notation: a relaxation
delay of 3.5 s; an acquisition time of 2.32 s; 256 transients;
TD of 64 k; SW of 20.01 ppm. This excitation sculpting
(ZGESGP) pulse sequence allowed obtaining the best
water signal quenching and recording the high quality 1H
NMR spectra. Spectra were processed with line broadening
of 0.3 Hz and manually phased and baseline corrected
using Topspin 1.3 software (Bruker, GmBH, Germany) and
referenced to a-glucose signal d = 5.225 ppm for the
serum samples and to the TSP resonance at d = 0.0 ppm
for the urine and EBC samples. The correction of peak
positions (alignment) was done using the correlation opti-
mized warping algorithm, COW, and the icoshift algorithm
implemented in Matlab (Matlab v. 8.1, Mathworks Inc.).
The spectra were normalized using the Probabilistic Quo-
tient Normalization (PQN) method. Finally, the dataset was
binned into 14,375 integrals (serum) of an equal width
(0.001 ppm), 14,625 integrals (urine) of equal width
(0.005 ppm) and 14,125 integrals (EBC) of an equal width
(0.001 ppm).
2.5 Preprocessing of variables prior to analysis
A total of 31 serum, 27 urine and 16 EBC metabolites
were analyzed. The concentration of any metabolite was
obtained using NMR as a signal integral of the
Table 1 Demographic data and clinical profiles of patients included
in the study
COPD OSA
Number of patients 18 28
Sex (male/female) 9/9 23/5
Age (mean/range) 64/(49–81) 54/(27–65)
Body mass index
(mean/range)
30/(20–33) 25/(22–41)
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non-overlapping resonances (or a cluster of partly over-
lapping resonances). The metabolite resonances were
identified according to assignments published in the lit-
erature and in on-line databases (Biological Magnetic
Resonance Data Bank and Human Metabolome Data
Base). The median 1H NMR spectra of serum, urine and
EBC in individuals with COPD are presented in Fig. 1.
2.6 Discriminant analysis for the identification
of biomarkers
The discriminant version of the Partial Least Squares re-
gression with the bootstrap procedure for estimating the
quality of the models with selected variables was adopted
and the prediction for a test set was estimated. The model
samples were chosen with the Kennard and Stone algo-
rithm applied separately to each group in order to guarantee
the representativity of the model set and to avoid the
possibility of having outlying samples in the test set. The
autoscaled (variables of all three biofluid blocks) data set
for each group was considered in the Kennard and Stone
algorithm, since the Euclidean distance is used as a simi-
larity measure between two samples. The model set should
also be balanced (containing the same number of samples
from each group) in order to avoid the weighting of the
discriminant cut-off value for the response variable (Br-
ereton and Lloyd 2014). Therefore, 13 samples (75 % of
the samples from the less numerous group) were selected
from each group. The remaining samples (15 OSAS sam-
ples and five COPD samples) formed the test set. As was
mentioned earlier, in order to reduce the chances of over-
fitting due to the larger number of variables with respect to
the number of samples mainly in the two- and three-block
PLS-DA models and to enable the easier interpretation of
the models, variable selection using the VIP-scores (An-
dersen and Bro 2010; Gosselin et al. 2010; Kvalheim and
Karstang 1989) or SR (Rajalahti et al. 2009) was per-
formed. The VIP-score is a quantitative measure that
indicates the contribution of a single variable to the de-
scription of both independent variables and the response
variable, while the SR is ratio of the explained variance to
the residual variance of a variable after target projection
transformation. The VIP-score and SR for each variable
were estimated 1000 times using the bootstrap procedure
with a replacement. The two procedures will be abbrevi-
ated as VIP-PLS-DA or SR-PLS-D in the rest of the text.
The main steps of the data modeling procedure are pre-
sented in Fig. 2. This general methodology was also fol-
lowed in the analysis of data containing the metabolites
that are present in one or two biofluids.
The variables that had an average VIP-scores or SRs
below a given cut-off value were discarded from the final
model. The selection of an appropriate cut-off value for
VIPs or SRs is an important issue. In general, a variable
that has a unitary VIP-score is highly influential since the
average of the squared values of the VIPs is equal to 1.0.
Even though the unitary cut-off value is often used, some
researchers have found it to be too restrictive. Other au-
thors have stressed that this value depends on the data
structure and that an important variable may have a VIP-
score of more than 0.8. Here, we have chosen a cut-off
value of 0.8 after a preliminary investigation of the
uncertainty in the estimation of the VIPs. A similar boot-
strap VIP-PLS-DA methodology was also used for the
selection of wavelengths in a spectral imaging dataset
(Kvalheim and Karstang 1989). Moreover, some authors
(Andersen and Bro 2010) have pointed out that applying a
variable selection that is based on the VIP-scores only once
is usually ineffective due to the large number of variables
that remain and therefore, it has been proposed that the
selection procedure be repeated several times. In this re-
search work, we repeated the whole VIP procedure three
times. Thus, for each bootstrap sample (a sample formed
by re-sampling the original data populations with a re-
placement) of the model set, a PLS-DA model of certain
complexity that was chosen based on a leave-one-out
cross-validation procedure is selected and the VIP-scores
or SR after the target projection transformation (Rajalahti
et al. 2009) were calculated. After considering 1000
bootstrap samples, the average value of the area under the
receiver operating curve (AUC) was calculated as a figure
of merit that described the model’s performance. The
standard error (uncertainty) in the AUC estimation (se)b,
with b bootstrap samples (b = 1 000) is defined as follows:
ðse)b ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
P
b
i¼1
ðhi  hÞ2
b  1
v
u
u
u
t
ð1Þ
In this equation, hi is the estimate of the AUC for the
i-th bootstrap sample and h is the mean estimate of the
AUC for all of the bootstrap samples.
The variables with average VIP-scores below 0.8 were
removed. The cut-off value for SR can be estimated using
the F-test, since SR is defined as the ratio between the
variable variance that is explained in the PLS-DA model of
a certain complexity and its residual variance after target
projection transformation. Since the values of the F-dis-
tribution tend to 1.0, a unitary cut-off value can be used. In
this work, we selected the cut-off value of SR based on the
so-called discriminating variable test, the DIVA test, and
the SR plots that have been proposed in the literature
(Kvalheim et al. 2014). Unlike the VIP-PLS-DA, the
bootstrap SR-PLS-DA methodology was applied once to
each dataset and variables with an average SRs found be-
low a given cut-of value, which were chosen after an
Fusion of the 1H NMR data of serum, urine and exalted breath condensate in order to… 1567
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inspection of the DIVA and SR plots, were discarded from
the final model. The prediction performance of the final
model was estimated using the independent test set, which
was not used during the construction of the model and
variable selection. The respective AUC value, sensitivity,
specificity and efficiency for the test set were also calcu-
lated. For the two-group problem that was studied in this
work, sensitivity is defined as the percentage of samples
from the OSAS group of patients that were correctly pre-
dicted by the model, while specificity is the percentage of
samples that were collected from patents with COPD that
were properly predicted as having COPD. The best model
would have a sensitivity and a specificity of 100 %. One
can also define the so-called efficiency, also known in the
literature as the non-error rate, which is the total percentage
of test samples that are correctly classified.
Fig. 1 The median of 1H NMR spectra of the a serum COPD
samples: 1a L1; 2a L2; 3a Leucine; 4a Valine; 5a Isoleucine; 6a
Isobutyrate; 7a Unk_1; 8a 3-Hydroxybutyrate; 9a L3; 10a Lactate;
11a Alanine; 12a L4; 13a Acetate; 14a L5; 15a NAC1; 16a NAC2;
17a Unk2; 18a Pyruvate; 19a Succinate; 20a Glutamine; 21a Citrate;
22a Creatine; 23a Creatinine; 24a Choline; 25a GPC ? APC; 26a
Unk_2; 27a Glucose; 28a L6; 29a Tyrosine; 30a Histidine; 31a
Phenylalanine; b urine COPD samples: 1b Isobutyrate; 2b Methyl-
succinate; 3b 3-Aminoisobutyrate; 4b Methylmalonate; 5b 3-Hy-
droxyisovalerate; 6b Lactate; 7b 2-Hydroxyisobutyrate; 8b Alanine;
9b Acetate; 10b Unk_1; 11b Unk_2; 12b Citrate; 13b Dimethylamine;
14b N,N-Dimethylformamide; 15b sn-Glycero-3-phosphocholine; 16b
Creatine; 17b Creatinine; 18b Trimethylamine N-oxide; 19b Glycine;
20b Glycolate; 21b Unk_3; 22b Trigonelline; 23b cis_Aconitate; 24b
Hydroxyphenyl; 25b N-Phenylacetylglycine; 26b Hippurate; 27b
Xanthine; 28b Formate; c EBC COPD samples: 1c Butyrate; 2c
Propionate; 3c Propylene glycol; 4c Ethanol; 5c 3-Hydroxyisovaler-
ate; 6c acetate; 7c Unk_1; 8c Acetate; 9c Acetone; 10c Unk_2; 11c
Methanol; 12c Unk_3; 13c Isopropanol; 14c Phenol; 15c Unk_4; 16c
Formate
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All calculations using in-house implemented routines
were performed with MATLAB 7.0 (R14) on a personal
computer (Intel(R) Pentium(R) M, 1.60 GHz with 2 GB
RAM) using the Microsoft Windows XP (service pack 2)
operating system.
3 Results and discussion
Several discriminant models were built. Firstly the quality
of the models for the individual blocks of variables (EBC,
serum, urine), two blocks of variables and the three-block
variables were evaluated using the bootstrap procedure
with a replacement. The histograms of the AUC values that
were obtained from the bootstrap procedure (the average
AUC value for each model is shown as a vertical red line)
are presented in Fig. 1S (Supplementary materials) and
Table 2, while the sensitivity, specificity and efficiency of
prediction are listed in Table 3.
From the values that are presented in Tables 2 and 3, one
can conclude that the models that solely exploit the serum or
urine variables show relatively good prediction capabilities
(AUCtest(serum) = 0.91 and AUCtest(urine) = 0.93). Four
OSAS samples were incorrectly predicted as COPD samples
using serum variables, which results in a sensitivity of
73.33 %, while only two OSAS samples (a sensitivity of
86.67 %) were wrongly predicted by the model using all of the
urine variables. Both models show the highest specificity of
100 % thus indicating the best prediction of the COPD sam-
ples. The uncertainty in the AUC estimation of the serum
model is larger than the uncertainty that was obtained for the
urine model (Fig. 1S; Table 2). The model using only
EBC variables had a poor prediction performance
(AUCtest = 0.52), which indicates that there are some dif-
ferences between the model and test samples. In fact, the
model has a relatively high sensitivity of 80 %, but a very low
specificity of 20 %. This suggests that the probability of the
correct identification of a patient with the OSA syndrome is
high with this EBC model, although the probability of a cor-
rect COPD identification is very low. Thus, there is a high risk
that a patient with developed COPD may be diagnosed with
the OSA syndrome using this model. The models that combine
the EBC variables with either serum or urine metabolites have
somewhat lower specificities in comparison to the models that
were built using all of the serum or urine metabolites only.
Compared to the model that used only the serum metabolites,
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Fig. 2 A general scheme of the data analysis procedure with the main steps highlighted. The methodology is illustrated on a data set containing
the metabolites of EBC, serum and urine biofluids
Fusion of the 1H NMR data of serum, urine and exalted breath condensate in order to… 1569
123
the model using both EBC and serum metabolites had the
same sensitivity and a lower specificity of 80 %. This suggests
that the probability of identifying a COPD patient as a patient
with the OSA syndrome is higher with the model of the two
types of metabolites than the probability that is estimated with
the model using only the serum metabolites. The model using
both EBC and urine metabolites presents a slightly lower
sensitivity of 80 % and a poorer specificity of 60 % in com-
parison to the model that was built for the urine metabolites
only. This indicates that the inclusion of the EBC variables
results in an incorrect prediction of the COPD samples as the
OSA samples. The model using both the serum and urine
metabolites, which had a sensitivity of 73.33 % and a speci-
ficity of 100 %, had a comparable prediction performance
(AUCtest = 0.95) to the models that were built for either the
serum or urine metabolites. However, from a practical point of
view, the analysis of one biofluid is the easiest and the most
preferable. The main question is whether a limited number of
variables (possible biomarkers) would still provide a good
discrimination of the two groups of patients that were studied
and a good prediction performance of the models. The average
AUC values for the model sets and the respective test sets with
different sets of metabolites, which were obtained using the
VIP-PLS-DA and SR-PLS-DA methods, are presented in
Table 4. The cut-off values for the average SRs are also pre-
sented therein. As was mentioned earlier, the cut-off values for
the average SRs were determined using the so-called dis-
criminating variable test, the DIVA test. The DIVA test is a
nonparametric test in which the relation of the mean correct
classification rate, MCCR, for variables found in a given SR
interval is examined. The mean correct classification rate in-
creases with the increasing values of SR which provides a
quantitative measure of the discriminatory ability in the whole
range of SR intervals (Rajalahti et al. 2009). The values of the
prediction figures of merit for the sets of metabolites are
shown in Table 5 and the respective histograms for several
selected models are shown in Fig. 2S (Supplementary
materials).
Reducing the number of EBC metabolites based on the
average VIP-scores and SRs that were obtained from the
bootstrap PLS-DA method did not result in a better iden-
tification of individuals with COPD, which was indicated
by the poor specificities of 20 % (Table 5). The same
predictive performance, a sensitivity of 73.33 % and a
specificity of 80.00 %, was observed for the models that
were constructed with either the serum or urine variables
that were found using VIP-PLS-DA. Compared to VIP-
PLS-DA, the PLS-DA model using a subset of urine
metabolites that was obtained using the SR procedure, had
a slightly improved sensitivity and specificity of 86.67 and
100 %, respectively, while the model that was built for a
subset of serum metabolites had only a slightly improved
sensitivity. Serum and urine body fluids contain different
metabolites, but both of the subsets that were obtained
using VIP-PLS-DA showed the same potential to distin-
guish between individuals with COPD and those that had
been diagnosed with the OSA syndrome. The subsets of
serum metabolites that were found using the SR and VIP
methods contained the same eleven variables (see Table 6),
although it appears that the inclusion of L2, Leucine,
Table 2 The average AUC
values (±uncertainty in the
AUC estimation) for the model
set and the AUC values for the
test set obtained from PLS-DA
with all variables
Variables Average AUC values for model set AUCtest
EBC 0.92 ± 0.05 0.52
Serum 0.88 ± 0.06 0.91
Urine 0.94 ± 0.04 0.93
EBC ? serum 0.94 ± 0.04 0.91
EBC ? urine 0.98 ± 0.02 0.81
Serum ? urine 0.94 ± 0.04 0.95
EBC ? serum ? urine 0.96 ± 0.03 0.91
Table 3 Sensitivity, specificity
and efficiency for the test set of
the PLS-DA model with all
variables
Variables PLS-DA
(complexity)
Sensitivity (%) Specificity (%) Efficiency (%)
EBC 1 80.00 20.00 65.00
Serum 1 73.33 100.00 80.00
Urine 1 86.67 100.00 90.00
EBC ? serum 1 73.33 80.00 75.00
EBC ? urine 1 80.00 60.00 75.00
Serum ? urine 1 73.33 100.00 80.00
EBC ? serum ? u rine 1 66.67 80.00 70.00
1570 A. Za˛bek et al.
123
Lactate, L6, NAC1, NAC2 and the removal of L1 and
GPC ? APC serum metabolites leads to an improvement
in the model’s prediction.
Moreover the larger number of urine metabolites that
were selected using the SR approach in comparison to VIP-
PLS-DA as well as the fact that only five variables were
found to be common for both sets of urine metabolites may
explain the improved value of specificity.
Several important observations are apparent when
comparing the prediction abilities of models with all of the
variables and the reduced number of two-block variables.
Compared to the model with all EBC and serum metabo-
lites, the model with the subset of EBC and serum
metabolites that were found using SR-PLS-DA had an
improved sensitivity of 86.67 % and the same specificity of
80.00 %. The model using a subset of serum variables that
were selected using the SR method had the same perfor-
mance. In fact, none of the EBC metabolites were selected
in the PLS-DA model and the serum metabolites were the
same as those found using the SR-PLS-DA that was built
for serum metabolites only. This confirms the previous
observation that the EBC metabolites have a lower poten-
tial for the correct discrimination of COPD and OSAS
patients than the serum metabolites.
The model with the EBC and urine variables that were
selected with the SRs over 0.4 (see Tables 3, 5) had the
same prediction performance as the model using all of the
EBC and urine metabolites. Only two EBC metabolites
(Propylene glycol, Formate ?) were considered in this
model (see Table 6). These two EBC metabolites appear to
be strongly related to the development of the OSA syn-
drome in patients. In contrast, the model with the EBC and
urine metabolites that had the largest VIP scores had a poor
prediction performance (AUCtest = 0.63) with a low sen-
sitivity and specificity of 66.67 and 60.00 %, respectively.
The model that was built for serum and urine metabo-
lites that were selected using SR-PLS-DA had the same
prediction features (sensitivity of 73.33 % and a specificity
Table 4 The AUC values for the model (±uncertainty in the AUC estimation) and test sets with selected variables from VIP-PLS-DA and SR-
PLS-DA
Variables Variable selection using VIP-PLS-DA Variable selection using SR-PLS-DA
Average AUC values for model
set
AUCtest Average AUC values for model
set
AUCtest Cut-off value of SR (MCCR
[%])
EBC 0.93 ± 0.05 0.48 0.90 ± 0.06 0.48 0.3 (60)
Serum 0.87 ± 0.06 0.92 0.97 ± 0.03 0.88 0.8 (62)
Urine 0.98 ± 0.02 0.83 0.90 ± 0.06 0.95 0.4 (60)
EBC ? serum 0.92 ± 0.04 0.85 0.97 ± 0.03 0.88 0.8 (62)
EBC ? urine 0.99 ± 0.01 0.63 0.91 ± 0.05 0.89 0.4 (60)
Serum ? urine 0.92 ± 0.05 0.93 0.88 ± 0.05 0.93 0.5 (61)
EBC ? serum ? urine 0.94 ± 0.03 0.92 0.97 ± 0.03 0.91 0.6 (62)
The mean correct classification rates, MCCRs, which were estimated for the cut-off values of the average SRs, are also listed
Table 5 Sensitivity, specificity and efficiency for the test sets with variables selected by VIP-PLS-DA and SR-PLS-DA
Variables VIP-PLS-DA
(complexity)
SR-PLS-DA
(complexity)
Sensitivity (%) Specificity (%) Efficiency (%)
VIP-PLS-
DA
SR-PLS-
DA
VIP-PLS-
DA
SR-PLS-
DA
VIP-PLS-
DA
SR-PLS-
DA
EBC 1 1 80.00 73.33 20.00 20.00 65.00 60.00
Serum 1 2 73.33 86.67 80.00 80.00 75.00 85.00
Urine 2 1 73.33 86.67 80.00 100.0 75.00 90.00
EBC ? serum 1 2 73.33 86.67 80.00 80.00 75.00 85.00
EBC ? urine 1 1 66.67 80.00 60.00 60.00 65.00 75.00
Serum ? urine 1 1 66.67 73.33 80.00 100.0 70.00 80.00
EBC ? serum ? urine 1 2 60.00 86.67 80.00 60.00 65.00 80.00
The optimal complexities of the final models are also listed
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of 100 %) as the one that was constructed for all of the
serum and urine metabolites. Compared to these models,
the model using only ten urine metabolites that were se-
lected from SR-PLS-DA also showed a specificity of
100 % although it had a better sensitivity of 86.67 %.
Specifically, this model (AUCtest = 0.95) had the best
prediction performance in comparison to all of the other
models that were constructed (Tables 4, 5).
In general, it appears that urine metabolites present the
highest probability for the correct identification of indi-
viduals with COPD and the lowest probability for the in-
correct identification of the OSA syndrome as developed
COPD. Specifically, the results showed that only ten urine
metabolites may be sufficient for the development of a
metabolomic diagnostic procedure. It should be pointed out
that the collection of samples was not large enough to draw
Table 6 Variables selected by the VIP-PLS-DA and SR-PLS-DA methods in all models constructed
Block(s) of
variables
Variables selected using VIP-PLS-DA Variables selected using SR-PLS-DA Percentage
of common
variables
EBC Propylene glycol, ethanol, 3-hydroxyisovalerate, acetone,
methanol, Unk2 (d = 2.90 ppm)a, Unk3
(d = 3.57 ppm), Unk4 (d = 7.07 ppm), formate
Propylene glycol, ethanol, 3-hydroxyisovalerate,
methanol, Unk2 (d = 2.90 ppm), Unk3
(d = 3.57 ppm), isopropanol, formate
44 (7 vars)
Serum L1, L3, L4, L6, isoleucine, Unk1 (d = 1.11 ppm), Unk2
(d = 2.22 ppm), Unk3 (d = 4.26 ppm), acetate,
glutamine, choline, GPC ? APC, histidine,
phenylalanine
L2, L3, L4, L6, leucine, isoleucine, Unk1
(d = 1.11 ppm), Unk2 (d = 2.22 ppm), Unk3
(d = 4.26 ppm), lactate, acetate, L6, NAC1,
NAC2, glutamine, choline, histidine, phenylalanine
39 (12 vars)
Urine Isobutyrate, 3-aminoisobutyrate, 2-hydroxyisobutyrate,
Unk2 (d = 2.35 ppm), N,N-dimethylglycine, sn-
glycero-3-phosphocholine, creatine, creatinine,
xanthine, Formate
Isobutyrate, methylsuccinate, 3-hydroxyisovalerate,
lactate, 2-hydroxyisobutyrate, Unk2
(d = 2.35 ppm), N,N-dimethylglycine, sn-glycero-
3-phosphocholine, cis_Aconitate, Formate
18 (5 vars)
EBC? Propylene glycol, 3-Hydroxyisovalerate, Methanol,
Formate ?
23 (11 vars)
Serum L1, L3, L4, L6, isoleucine, Unk1 (d = 1.11 ppm), Unk3
(d = 4.26 ppm), acetate, choline, glutamine,
GPC ? APC, histidine, phenylalanine
L2, L3, L4, L6, leucine, isoleucine, Unk1
(d = 1.11 ppm), Unk2 (d = 2.22 ppm), Unk3
(d = 4.26 ppm), lactate, acetate, L6, NAC1,
NAC2, glutamine, choline, histidine, phenylalanine
EBC? propylene glycol, ethanol, 3-Hydroxyisovalerate, Unk2
(d = 2.90 ppm), methanol, isopropanol, formate ?
Propylene glycol, formate ? 18 (8 vars)
Urine Isobutyrate, 3-aminoisobutyrate, 2-hydroxyisobutyrate,
Unk2 (d = 2.35 ppm), N,N-dimethylglycine, sn-
glycero-3-phosphocholine, creatine, creatinine,
trimethylamine N-oxide, xanthine, formate
Isobutyrate, methylsuccinate, methylmalonate,
3-hydroxyisovalerate, lactate,
2-hydroxyisobutyrate, Unk2 (d = 2.35 ppm), N,N-
dimethylglycine, sn-glycero-3-phosphocholine,
cis_aconitate, formate
Serum? L1, L3, L4, L6, isoleucine, Unk1 (d = 1.11 ppm), Unk3
(d = 4.26 ppm), acetate, choline, glutamine,
GPC ? APC, histidine, phenylalanine
L2, L3, L4, L6, leucine, isoleucine, Unk1
(d = 1.11 ppm), Unk2 (d = 2.22 ppm), Unk3
(d = 4.26 ppm), isobutyrate, lactate, acetate, L6,
NAC1, NAC2, glutamine, citrate, creatinine,
choline, GPC ? APC, histidine, phenylalanine ?
25 (15 vars)
Urine Isobutyrate, 2-hydroxyisobutyrate, N,N-dimethylglycine,
sn-glycero-3-phosphocholine, creatine, creatinine,
formate
2-Hydroxyisobutyrate, Unk2 (d = 2.35 ppm), N,N-
dimethylglycine, sn-glycero-3-phosphocholine
EBC? Propylene glycol, 3-Hydroxyisovalerate, Methanol,
Formate ?
20 (15 vars)
Serum? L1, L2, L3, L4, L6, valine, isoleucine, Unk1
(d = 1.11 ppm), Unk_2 (d = 2.22 ppm), Unk3
(d = 4.26 ppm), acetate, glutamine, choline,
GPC ? APC, histidine, phenylalanine ?
L1, L2, L3, L4, L6, isoleucine, Unk1
(d = 1.11 ppm), Unk2 (d = 2.22 ppm), Unk3
(d = 4.26 ppm), lactate, acetate, glutamine,
choline, L6, NAC_1,NAC_2, citrate, GPC ? APC,
histidine, phenylalanine ?
Urine Isobutyrate, 2-hydroxyisobutyrate, N,N-dimethylglycine,
sn-glycero-3-phosphocholine, creatine, creatinine,
formate
N,N-Dimethylglycine
a The notation Unk2 (d = 2.90 ppm) means an unknown metabolite at a chemical shift of 2.90 ppm
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general conclusions and a larger set of samples will be
necessary for the further validation of this procedure.
Moreover, several studies have emphasized the possibility
of using changes in the EBC metabolite levels for the
correct identification of individuals with OSAS or indi-
viduals with COPD from healthy individuals. The results of
this study indicate that changes in the level of EBC
metabolites may not be specific enough to correctly iden-
tify COPD patients from individuals with OSAS and
therefore, a large number of false positive identifications
may occur.
4 Concluding remarks
The main conclusion of this study is that only ten urine
metabolites are enough to distinguish COPD patients from
those with the OSA syndrome. The urine metabolites were
selected using the SR approach. The model with a speci-
ficity of 100 % and a sensitivity of 86.67 % also presents
the best prediction performance (AUCtest = 0.95) in com-
parison to all of the other models that were constructed. It
appears that a combination of two biofluid metabolites or
metabolites of all three types of biofluids is unnecessary to
obtain a diagnostic model with improved predictive abil-
ities. Perhaps a surprising conclusion is that changes in the
concentration in the EBC metabolites were not specific
enough to predict correctly the COPD or OSAS in indi-
viduals, which was illustrated by the poor performance of
the discriminant models that were constructed for those
variables.
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